1) tenonitrozole
替诺尼唑
2) tizoxanide
替唑尼特
1.
Determination of Enzymatic Hydrolysis Conditions of Tizoxanide Conjugate
替唑尼特结合物酶解条件的确定
2.
Nitazoxanide,a new broad-spectrum parasiticidal agent was rapidly deacetylated to tizoxanide,followed by the formation of glucurono-conjugate after dog oral administration.
硝唑尼特经狗口服后在体内迅速代谢成替唑尼特,随后替唑尼特进一步与葡萄糖醛酸结合生成了葡萄糖醛酸替唑尼特结合物。
3.
We refined tizoxanide and worked out its content is 99.
具体研究内容如下： 精制了替唑尼特(tizoxanide，简称T)样品，用面积归一化法测得其含量为99。
3) Tinazoline
替那唑唑
4) sunitinib
舒尼替尼
1.
Advance in research of sunitinib,a multitargeted receptor tyrosine kinase inhibitor;
多靶点酪氨酸激酶抑制剂舒尼替尼的研究进展
2.
Pharmaceutical Care of Clinical Pharmacist for a Cancer Patient Taking Molecular Targeted Drug:Sunitinib
临床药师对1例服用分子靶向药物舒尼替尼的肿瘤患者的药学监护
5) nilotinib
尼罗替尼
1.
Pharmacology and clinical evaluation of nilotinib,a Bcr-Abl tyrosine kinase inhibitor;
Bcr-Abl激酶抑制剂尼罗替尼的药理与临床评价
2.
After deprotection, the antitumor agent nilotinib was obtained with an overall yield of 40% based on compound 5.
另用3-氨基-4-甲基苯甲酸乙酯(5)与氨腈成胍6,6与3-二甲胺基-1-(3-吡啶基)-2-丙烯-1-酮环合得4-甲基-3-[[4-(3-吡啶基)-2-嘧啶基]氨基]苯甲酸乙酯(8),8经叔丁氧羰基保护、水解,再与4经酰胺化、脱保护后得到尼罗替尼,总收率40%(以5计)。
6) Tenofovir
替诺福韦
1.
Effect of Cationic Liposome Formulation on Human Carcinoma Hepatic SMMC-7721 Cells' Uptake of Tenofovir and Cytotoxicity;
替诺福韦阳离子脂质体的制备及其对人体肝细胞SMMC-7721摄取和细胞毒性研究
2.
Study on pharmacokinetics of tenofovir disoproxil fumarate capsules in healthy volunteers;
富马酸替诺福韦酯胶囊在健康人体内的药动学研究
3.
Cationic Liposome Formulations of Tenofovir and Their Role in Enhancing Hepatocyte Uptake;
替诺福韦阳离子脂质体的制备和细胞摄取研究
补充资料：替诺尼唑
分子式：
CAS号：
性质：又名台洛硝腺。可从二噁烷或DMF中得到结晶，熔点255～256℃。以2-氨基-5-硝基-噻唑为原料。经缩合制得。本品属于杀滴虫、抗感染药物。口服或阴道放置可治疗阴道毛滴虫病，亦有抗白色念球菌作用。
CAS号：
性质：又名台洛硝腺。可从二噁烷或DMF中得到结晶，熔点255～256℃。以2-氨基-5-硝基-噻唑为原料。经缩合制得。本品属于杀滴虫、抗感染药物。口服或阴道放置可治疗阴道毛滴虫病，亦有抗白色念球菌作用。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条